ES2854708T3 - Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos - Google Patents
Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos Download PDFInfo
- Publication number
- ES2854708T3 ES2854708T3 ES17200006T ES17200006T ES2854708T3 ES 2854708 T3 ES2854708 T3 ES 2854708T3 ES 17200006 T ES17200006 T ES 17200006T ES 17200006 T ES17200006 T ES 17200006T ES 2854708 T3 ES2854708 T3 ES 2854708T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- cells
- antibodies
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010038498 Interleukin-7 Receptors Proteins 0.000 title claims abstract description 13
- 102000010782 Interleukin-7 Receptors Human genes 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title description 10
- 229940079593 drug Drugs 0.000 title description 4
- 239000003814 drug Substances 0.000 title description 4
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims abstract description 100
- 210000004027 cell Anatomy 0.000 claims abstract description 96
- 241000282414 Homo sapiens Species 0.000 claims abstract description 63
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 54
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 38
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 38
- 229940100994 interleukin-7 Drugs 0.000 claims abstract description 38
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 36
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 27
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 24
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 21
- 102000049284 human IL7R Human genes 0.000 claims abstract description 11
- 230000001419 dependent effect Effects 0.000 claims abstract description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000005784 autoimmunity Effects 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000011285 therapeutic regimen Methods 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000005889 cellular cytotoxicity Effects 0.000 claims 1
- 230000000869 mutational effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 description 100
- 230000027455 binding Effects 0.000 description 37
- 108091033319 polynucleotide Proteins 0.000 description 34
- 102000040430 polynucleotide Human genes 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 11
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 102000052622 human IL7 Human genes 0.000 description 11
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000033581 fucosylation Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 4
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 4
- 201000003791 MALT lymphoma Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002871 immunocytoma Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000003614 tolerogenic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000045535 human TSLP Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306353.1A EP2583980A1 (en) | 2011-10-19 | 2011-10-19 | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2854708T3 true ES2854708T3 (es) | 2021-09-22 |
Family
ID=47018987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17200006T Active ES2854708T3 (es) | 2011-10-19 | 2012-10-04 | Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9447182B2 (OSRAM) |
| EP (3) | EP2583980A1 (OSRAM) |
| JP (2) | JP2014532074A (OSRAM) |
| ES (1) | ES2854708T3 (OSRAM) |
| WO (1) | WO2013056984A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2482342B1 (es) * | 2012-12-27 | 2015-07-02 | Consejo Superior De Investigaciones Científicas (Csic) | TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| CN107073113A (zh) | 2014-10-18 | 2017-08-18 | 辉瑞大药厂 | 抗il‑7r抗体组合物 |
| CN107438620A (zh) | 2015-03-31 | 2017-12-05 | 韦斯夸尔德有限公司 | 多肽 |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| KR20180037056A (ko) * | 2015-09-22 | 2018-04-10 | 화이자 인코포레이티드 | 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| MD3423496T2 (ro) * | 2016-02-29 | 2020-01-31 | Ose Immunotherapeutics | Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul cancerului |
| RU2769352C2 (ru) | 2016-12-09 | 2022-03-30 | Осе Иммьюнотерапьютикс | Антитела и полипептиды, направленные против cd127 |
| EP3606548A4 (en) * | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL AGENT FOR THE TREATMENT OF CANCER |
| US12258577B2 (en) | 2017-08-29 | 2025-03-25 | Ose Immunotherapeutics | Method effector cells using anti-CD127 antibodies for applications in cell therapy |
| KR102570405B1 (ko) * | 2019-01-22 | 2023-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| WO2020254828A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Compositions |
| CN114514243B (zh) | 2019-06-21 | 2025-01-24 | 索瑞索制药公司 | 多肽 |
| CA3250546A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | IL7R MODULATOR ACTIVITY BIOMARKERS |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025089399A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人国立がん研究センター | インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ） |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007140472A2 (en) * | 2006-05-31 | 2007-12-06 | The Regents Of The University Of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| CN105001332B (zh) * | 2007-05-21 | 2018-12-04 | 奥尔德生物控股有限责任公司 | 针对il-6的抗体及其用途 |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) * | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| US8815242B2 (en) * | 2009-05-27 | 2014-08-26 | Synageva Biopharma Corp. | Avian derived antibodies |
| AR080027A1 (es) * | 2010-01-28 | 2012-03-07 | Glaxo Group Ltd | Proteinas de union a cd127 |
| US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
-
2011
- 2011-10-19 EP EP11306353.1A patent/EP2583980A1/en not_active Withdrawn
-
2012
- 2012-10-04 EP EP12772749.3A patent/EP2768860A1/en not_active Withdrawn
- 2012-10-04 JP JP2014536177A patent/JP2014532074A/ja active Pending
- 2012-10-04 EP EP17200006.9A patent/EP3299392B1/en active Active
- 2012-10-04 ES ES17200006T patent/ES2854708T3/es active Active
- 2012-10-04 WO PCT/EP2012/069670 patent/WO2013056984A1/en not_active Ceased
- 2012-10-04 US US14/352,992 patent/US9447182B2/en active Active
-
2017
- 2017-05-30 JP JP2017106295A patent/JP6621778B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140308281A1 (en) | 2014-10-16 |
| JP2017184753A (ja) | 2017-10-12 |
| EP3299392B1 (en) | 2020-11-18 |
| EP2583980A1 (en) | 2013-04-24 |
| WO2013056984A1 (en) | 2013-04-25 |
| JP2014532074A (ja) | 2014-12-04 |
| EP2768860A1 (en) | 2014-08-27 |
| JP6621778B2 (ja) | 2019-12-18 |
| EP3299392A1 (en) | 2018-03-28 |
| US9447182B2 (en) | 2016-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2854708T3 (es) | Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos | |
| JP7488323B2 (ja) | 抗ｌａｇ－３抗体および組成物 | |
| US11440964B2 (en) | Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody | |
| AU2011223919B2 (en) | Therapeutic DLL4 binding proteins | |
| CN114728065A (zh) | 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 | |
| KR20120089659A (ko) | 치료용 ｄｌｌ4 결합 단백질 | |
| KR20190008171A (ko) | 항-bcma 폴리펩티드 및 단백질 | |
| KR102369118B1 (ko) | 인간화 항-basigin 항체 및 이의 용도 | |
| CN110172099B (zh) | 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途 | |
| JP2022537703A (ja) | 抗体および使用方法 | |
| KR102882299B1 (ko) | 항체 및 사용 방법 | |
| CN118804927A (zh) | 抗b7-h7抗体或其抗原结合片段及制备方法和应用 | |
| US20240269276A1 (en) | Specific binding protein targeting pd-l1 and cd73 | |
| KR20180089521A (ko) | Tnf 알파에 결합하는 항체 분자 | |
| CN120554509A (zh) | 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用 | |
| TWI833227B (zh) | 靶向pd-l1和cd73的特異性結合蛋白及其應用 | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
| HK40067877A (en) | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom | |
| JP2025537255A (ja) | 抗アルファ５インテグリン抗体及びその使用 | |
| HK40033623B (zh) | 结合pd-1的抗体 | |
| NZ793343A (en) | Anti- LAG-3 antibodies and compositions | |
| OA20097A (en) | Antibodies directed against CD127. |